The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effectiveness of erlotinib in lung adenocarcinomas with classic and alternative EGFR mutations detected by Roche 454 GS-FLX next-generation sequencing (NGS).
Gyula Ostoros
No relevant relationships to disclose
Veronika Sarosi
No relevant relationships to disclose
Laszlo Mandoky
Employment or Leadership Position - Rigel
Ferenc Pinter
Employment or Leadership Position - Key Property Solutions
Stock Ownership - KPS Diagnostics
Research Funding - Roche
Richard Schwab
Employment or Leadership Position - KPS Diagnostics
Stock Ownership - KPS Diagnostics
Research Funding - Roche
Istvan Petak
Employment or Leadership Position - KPS Diagnostics
Stock Ownership - KPS Diagnostics
Research Funding - Roche
Laszlo Urban
No relevant relationships to disclose